BOSTON and ROLLE, Switzerland, Feb. 18, 2025 /PRNewswire/ — SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the fourth quarter and full year 2024 before U.S. markets open on Tuesday, March 4, 2025. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CET.
The call will be webcast live on the SOPHiA GENETICS Investor Relations Website. Additionally, a replay will be available on the website after its completion.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform that analyzes complex multimodal data – including genomics, radiomics, clinical, biological, and digital pathology data – to generate real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn.
SOURCE SOPHiA GENETICS
--Data presented at the American College of Cardiology Annual Scientific Session show that the reduction…
Discover the Oral Probiotic That’s Reshaping Dental Health—Backed by 75,000+ Users and Groundbreaking Science ProDentim…
Rybelsus® reduced major adverse cardiovascular events by 14% vs placebo in adults with type 2…
– Lorundrostat 50 mg dose achieved a 15.4 mmHg absolute reduction and 7.9 mmHg placebo-adjusted…
NeuroQuiet Reviews NeuroQuiet VANCOUVER, WA, March 29, 2025 (GLOBE NEWSWIRE) -- NeuroQuiet Reviews In a…
Ozempic® improved maximum walking distance by 13% vs placebo in adults with type 2 diabetes…